Mastocytosis: One Word for Different Diseases

• Main Authors: Marianna Criscuolo, Luana Fianchi, Alessio M. E. Maraglino, Livio Pagano
• Format: Article
• Language: English
• Published: Adis, Springer Healthcare 2018-10-01
• Series: Oncology and Therapy
• Subjects: Anaphylaxis; Cladribine; Invasive procedures; Mastocytosis; Pregnancy; Systemic mastocytosis
• Online Access: http://link.springer.com/article/10.1007/s40487-018-0086-2
• ISSN: 2366-1070; 2366-1089

Abstract Mastocytosis is a neoplastic disease originating from tissue infiltration by transformed mast cells. The diagnosis requires a high grade of suspicion due to the large variety of presenting symptoms. The World Health Organization classification recognizes localized (cutaneous) and systemic forms of the disease, with these forms showing different degrees of aggressiveness. Mastocytosis is often a multiorgan disease, and its correct management requires a multidisciplinary team of experienced consultants to provide overall patient care. Bone marrow evaluation by molecular analyses, skeleton X-ray and abdominal scan together with allergologic and dermatologic evaluation constitute the essential diagnostic work-up for adult patients with mastocytosis. As clinical situations vary, treatment options range from the use of drugs to treat the symptoms, such as anti-H1 receptors and steroids, to UV irradiation, which is overwhelmingly used in patients with cutaneous mastocytosis (CM) or indolent systemic mastocytosis, to cytoreductive treatment to control life-threatening symptoms or organ damage in the more aggressive forms of the disease. Prognosis also widely differs among patients diagnosed with mastocytosis, with the spectrum ranging from an almost normal life expectancy for those with CM and to less than 1-year median overall survival for those with mast cell leukemia.